Document Detail

Different clinical courses and predictors of atrial fibrillation occurrence after transisthmic ablation in patients with preablation lone atrial flutter, coexistent atrial fibrillation, and drug induced atrial flutter.
MedLine Citation:
PMID:  15546305     Owner:  NLM     Status:  MEDLINE    
The aim of this prospective study was to compare the long-term follow-up after transisthmic ablation of patients with preablation lone atrial flutter, coexistent AF, and drug induced atrial flutter to determine if postablation AF followed a different clinical course and displayed different predictors in these groups. The study evaluated 357 patients who underwent transisthmic ablation for typical atrial flutter. These were divided into four groups according to their preablation history. Group A included patients with typical atrial flutter and without preablation AF (n=120, 33.6%). Group B included patients with preablation AF and spontaneous atrial flutter (n=132, 37.0%). Group C patients had preablation AF and atrial flutter induced by treatment with IC drugs (propafenone or flecainide) (n=63, 17.6%) Group D included patients with preablation AF and atrial flutter induced by treatment with amiodarone (n=42, 11.8%). During a mean follow-up of 15.2 double dagger 10.6 months (range 6-55 months) AF occurred more frequently in groups B (56.1%) and C (57.1%) patients than in groups A (20.8%, P <0.0001) and D (31.0%, P <0.0001) patients. The results of multivariate analysis revealed that different clinical and echocardiographical variables were correlated with postablation AF occurrence in the different groups. Patients with atrial flutter induced by amiodarone have a significantly lower risk of postablation AF than patients with spontaneous atrial flutter and AF, and those with atrial flutter induced by IC drugs. Different clinical and echocardiographical variables predict postablation AF occurrence in different subgroups of patients.
Emanuele Bertaglia; Aldo Bonso; Franco Zoppo; Alessandro Proclemer; Roberto Verlato; Leonardo Corò; Roberto Mantovan; Sakis Themistoclakis; Antonio Raviele; Pietro Pascotto;
Related Documents :
1758955 - Multiple sclerosis: the impact of physical impairment and cognitive dysfunction on soci...
7024325 - Yersinia enterocolitica: its isolation by cold enrichment from patients and healthy sub...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study    
Journal Detail:
Title:  Pacing and clinical electrophysiology : PACE     Volume:  27     ISSN:  0147-8389     ISO Abbreviation:  Pacing Clin Electrophysiol     Publication Date:  2004 Nov 
Date Detail:
Created Date:  2004-11-19     Completed Date:  2005-03-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7803944     Medline TA:  Pacing Clin Electrophysiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1507-12     Citation Subset:  IM    
Department of Cardiology, Ospedale Civile, Mirano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amiodarone / therapeutic use
Anti-Arrhythmia Agents / therapeutic use
Atrial Fibrillation / etiology*,  physiopathology,  surgery
Atrial Flutter / etiology*,  physiopathology
Catheter Ablation*
Cohort Studies
Disease-Free Survival
Flecainide / therapeutic use
Follow-Up Studies
Longitudinal Studies
Middle Aged
Propafenone / therapeutic use
Prospective Studies
Risk Factors
Time Factors
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 1951-25-3/Amiodarone; 54063-53-5/Propafenone; 54143-55-4/Flecainide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  An epicardial subxiphoid implantable defibrillator lead: superior effectiveness after failure of sta...
Next Document:  Relationship of baseline electrocardiographic characteristics with the response to cardiac resynchro...